By CHAD BRAY
The deal to acquire the specialty pharmaceutical company Rottapharm is expected to bolster Meda’s consumer health care business. It follows Meda’s fending off of a takeover approach from the American drug maker Mylan earlier this year.
Published: July 31, 2014 at 4:00AM
from NYT Business Day http://ift.tt/1n62ncK
from WordPress http://ift.tt/1uK2Zyn
via Hadi Aboukhater
No comments:
Post a Comment